AVEO Oncology (AVEO) Tops Q4 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. FLG
4. META
5. FICO
6. GMAB
7. ACCV
8. LLY
9. TSLA
10. SPCX

Go back to AVEO Oncology (AVEO) Tops Q4 EPS by 8c

AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results

March 14, 2022 7:00 AM EDT

Total 2021 Net Revenue of $42.3 Million

FOTIVDA® (tivozanib) U.S. Net Product Revenue of $38.9 Million since March 22, 2021

FOTIVDA U.S. Net Product Revenue of $16.8 Million for 4Q 2021, Driven by a 26% Increase in Prescriptions Filled Compared to 3Q 2021

Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100 to $110 Million

Long-term data from pivotal TIVO-3 study presented at ASCO GU 2022 continue to demonstrate durable disease control and positive trend for overall survival for FOTIVDA

... More